Back to Search
KFL&A Public Health is issuing an advisory regarding an increase in invasive meningococcal disease (type B) activity in the KFL&A area. In recent months, the region has experienced three confirmed cases of this serious bacterial infection, with no identifiable link between them. This count is above the KFL&A region’s historical average.
Invasive meningococcal disease (IMD) is a rare, but potentially life-threatening bacterial infection. It can infect the brain and spinal cord (meningitis), and the bloodstream (septicemia). All meningococcal infections are medical emergencies. Symptoms may initially resemble the flu, then rapidly worsen.
“Invasive meningococcal disease is a serious infection that can progress rapidly and have severe consequences if not treated promptly,” said Dr. Piotr Oglaza, medical officer of health at KFL&A Public Health. “It’s important to recognize the signs and symptoms of meningococcal disease and seek medical care immediately if illness is suspected.”
IMD symptoms can include:
- sudden fever
- intense headache
- stiff neck
- nausea
- vomiting
- sensitivity to light
- purplish skin rash
Meningococcal bacteria spreads person to person through close and direct contact (e.g., open-mouth kissing or sharing of drinking cups, eating utensils, vapes, etc).
Meningococcal B (MenB) vaccine is not routinely offered in Ontario except to people who have certain high-risk medical conditions. Meningococcal C vaccine is given at one year of age and meningococcal ACYW-135 vaccine is administered in Grade 7.
As we continue to work with partners to investigate, we encourage residents 25 years of age and under to ensure they are up-to-date with routine meningococcal vaccines. Individuals who do not meet the high-risk criteria for meningococcal B vaccine are encouraged to contact their health care provider to consider privately purchased immunization against meningococcal B.
For more information about invasive meningococcal disease and vaccination, visit kflaph.ca/IMD.
Subscribe